Scientech Research LLC Lowers Stake in Hims & Hers Health, Inc. $HIMS

by · The Markets Daily

Scientech Research LLC reduced its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 19.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,443 shares of the company’s stock after selling 8,163 shares during the quarter. Scientech Research LLC’s holdings in Hims & Hers Health were worth $988,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Smartleaf Asset Management LLC boosted its stake in shares of Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after acquiring an additional 227 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after acquiring an additional 388 shares in the last quarter. Larson Financial Group LLC lifted its stake in Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after buying an additional 458 shares in the last quarter. Finally, Cim LLC lifted its stake in Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after buying an additional 694 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of a number of research reports. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial decreased their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $38.92.

Get Our Latest Report on HIMS

Hims & Hers Health Trading Up 0.6%

Shares of Hims & Hers Health stock opened at $48.39 on Monday. The stock has a market cap of $10.94 billion, a P/E ratio of 60.49, a P/E/G ratio of 3.27 and a beta of 2.14. The stock’s 50 day simple moving average is $50.03 and its 200-day simple moving average is $45.10. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,107 shares of the business’s stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the transaction, the chief financial officer owned 63,222 shares in the company, valued at approximately $2,987,239.50. The trade was a 26.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $9,105,385.20. This trade represents a 26.09% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,390,328 shares of company stock worth $71,468,298. 17.71% of the stock is currently owned by insiders.

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Featured Stories

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Free Report).